M&A Deal Summary

Thermo Fisher Scientific Acquires HighChem

On June 6, 2019, Thermo Fisher Scientific acquired software company HighChem

Acquisition Highlights
  • This is Thermo Fisher Scientific’s 2nd transaction in the Software sector.
  • This is Thermo Fisher Scientific’s 1st transaction in Slovakia.

M&A Deal Summary
Date 2019-06-06
Target HighChem
Sector Software
Buyer(s) Thermo Fisher Scientific
Deal Type Add-on Acquisition

Target

HighChem

Bratislava, Slovakia
website
HighChem Ltd. is a developer of mass spectrometry software used to analyze complex data and identify small molecules in pharmaceutical and metabolomics laboratories. HighChem is based in Bratislava, Slovakia.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Thermo Fisher Scientific

Waltham, Massachusetts, United States

website

Category Company
Founded 1956
Sector Test/Measurement Equipment
Employees80,000
Revenue 32.2B USD (2020)
DESCRIPTION
Thermo Fisher's corporate headquarters in Waltham, Massachusetts.
Thermo Fisher's corporate headquarters in Waltham, Massachusetts.

Thermo Scientific is a provider of analytical instruments, laboratory equipment, software, services, consumables and reagents for better workflow solutions spanning sample preparation, sample analysis, and data interpretation. The Company was formed in 1956 and is based in Waltham, Massachusetts. Thermo Fisher Scientific was founded in 1956 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 52 of 62
Sector (Software) 2 of 2
Type (Add-on Acquisition) 46 of 55
Country (Slovakia) 1 of 1
Year (2019) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-24 Brammer Bio

Cambridge, Massachusetts, United States

Brammer Biopharmaceuticals LLC was founded early in 2015 to create a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO) to enable large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. With the in-depth biologics manufacturing knowledge and expertise of founders Mark Bamforth (CEO) and Steven Kasok (CFO), previously cofounders of Gallus Biopharmaceuticals, now as Brammer Bio, the company is positioned to accelerate the development of these important emerging technologies.

Buy $1.7B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-03-03 Qiagen N.V

Venlo, Netherlands

QIAGEN N.V. is a Netherlands holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Qiagen was founded in 1986 and is based in Venlo, the Netherlands.

Buy $11.5B
Mergr

Product

Company

Legal